Enable Registry in Phoenix: What to Know About Observational MS Research

When someone is living with relapsing multiple sclerosis (RMS), a research opportunity can raise practical questions: Is this a treatment trial? Will anything about my usual care change? What does “registry” mean? Arizona Neuroscience Research (ANR) currently lists the Enable study, also called TG1101-RMS406, as an observational registry for adults with relapsing forms of multiple sclerosis who have been prescribed BRIUMVI® (ublituximab-xiiy).

This article explains how registry research differs from a study that assigns treatment, what questions to bring to a research conversation, and why current study details should come directly from ANR’s team. It is general education only. It does not offer medical advice, recommend a medication, or promise that anyone will qualify, enroll, or benefit.

What is an observational registry?

A registry is a structured way to collect information over time. In the Enable listing, ANR describes a Phase 4 observational registry that follows real-world experience with BRIUMVI in adults with RMS. The listing says the registry collects information on safety, effectiveness, and patient experience in routine clinical practice over 96 weeks.

“Observational” is the key word. In general, observational research records what happens in ordinary care rather than randomly assigning people to a study treatment. That does not mean the experience is casual or unimportant. Registries use a protocol, consent process, defined data collection, and research oversight. It does mean that prospective participants should ask the research team exactly what the current protocol involves.

What an observational registry can—and cannot—answer

Registries can help researchers learn from a wider range of people than may be represented in an earlier controlled trial. They may record treatment patterns, side effects, outcomes reported by participants, laboratory information, clinic visits, and reasons treatment is continued or changed. Over time, this information can contribute to a clearer picture of how a medication is used in routine care.

At the same time, a registry does not guarantee a result for one person. People in everyday clinical care differ in many ways, including their MS history, other medical conditions, previous treatments, access to care, and life circumstances. Observational data can show patterns, but it may not prove that one specific outcome was caused by one specific treatment. That is why studies with different designs can each have a place in medical research.

How Enable is different from a treatment-assignment trial

Some clinical trials use random assignment and may compare an investigational medicine with another approach or placebo. The current ANR listing describes Enable differently: adults are already prescribed BRIUMVI as part of their care, and the registry follows real-world experience. The research team can explain whether the current protocol includes additional visits, questionnaires, records review, lab work, or other activities.

Do not assume that a registry changes your treatment plan, pays for routine care, or replaces your MS clinician. Those details depend on the current protocol, consent form, insurance and care arrangements, and the individual situation. Never start, stop, delay, or change a prescribed MS medicine based on a blog post or the possibility of joining a study.

Who may be invited to ask about Enable?

ANR’s Current Studies page says the registry is for adults with relapsing forms of MS who are prescribed BRIUMVI. That is a starting point, not an eligibility decision. Research studies have detailed inclusion and exclusion criteria, and the screening process is designed to protect participants and research quality.

If you are curious, it is reasonable to ask ANR whether the study is currently enrolling in Phoenix and what the first conversation involves. Be ready to share basic information requested by the team, such as your MS diagnosis history, current care provider, medication list, and whether BRIUMVI has been prescribed. The team will tell you which information is needed; you do not need to decide on your own whether you qualify.

Questions to bring to a registry conversation

Good questions help turn an unfamiliar research opportunity into an informed choice. Consider writing them down beforehand:

• Is Enable currently enrolling at this ANR location?
• Is my usual MS treatment already prescribed independently of the registry?
• What information will the registry collect, and how often?
• Which visits are research visits, and which are routine-care appointments?
• How long does participation last under the current protocol?
• Are there travel, scheduling, or technology requirements?
• What risks, inconveniences, or privacy considerations should I understand?
• Who will have access to my study information?
• Can I withdraw, and what happens to information already collected?
• Who should I contact if I have a new symptom or a concern?

The consent discussion should leave room for questions. You can ask for written materials, take time to read them, and discuss them with your regular care team or a trusted person before deciding whether to participate.

Why patient-reported experience is part of research

Tests, imaging, and clinic notes are useful, but they may not capture every part of day-to-day MS. Depending on the protocol, a registry may also ask participants about fatigue, mobility, work, family responsibilities, sleep, symptoms, or treatment experience. These are sometimes called patient-reported outcomes. They do not replace clinical measures; they add context about how life is going.

Answering in your own words and reporting both good and difficult days supports useful data. There is no “right” response. The purpose is not to please a research team or make a treatment look better or worse. Honest information, including changes that require clinical follow-up, is essential.

What privacy and consent usually involve

Before registry procedures begin, prospective participants should receive an informed-consent discussion. The consent form should explain the study purpose, what data may be collected, expected duration, possible risks or burdens, confidentiality protections, contacts for questions, and voluntary nature of participation. It should also explain what may happen if you decide to leave the study.

Privacy is important, but no study can promise zero risk. Ask how information is coded, stored, shared, and reported. Ask whether future research use is described and whether results are presented in a way that identifies individuals. A research coordinator can explain the language in the current consent materials. If something is unclear, pause and ask; signing consent should follow understanding, not pressure.

Keep routine MS care at the center

Research participation and clinical care are related but distinct. Your treating clinician remains the right person to discuss symptoms, treatment decisions, monitoring, and urgent concerns. A research team follows a study protocol and should tell you how to report study-related questions. Make sure you know whom to call after hours and what to do if symptoms worsen.

MS symptoms can change for many reasons, including infection, heat, sleep problems, medication effects, and disease activity. Do not assume a new or worsening symptom is “just part of the registry.” Contact your healthcare professional for personalized advice. If you have sudden neurologic symptoms, severe weakness, trouble speaking, new confusion, severe vision changes, chest pain, trouble breathing, or another emergency, call 911 or seek emergency care rather than waiting for a research response.

How to prepare before contacting ANR

Preparation can keep the first call simple. Have a current medication list, your questions, and the name of the clinician who manages your MS care. You may also want to note prior disease-modifying therapies, significant allergies, and any upcoming travel or procedures that could affect scheduling. Avoid sharing more health information than the team requests at the first contact; ANR staff will guide the screening process.

It can help to write down your goal for the conversation. Perhaps you want to understand what “observational” means, learn whether Enable is accepting participants, or clarify whether it fits alongside your current care. The goal is information first. Agreeing to a screening discussion does not require you to enroll.

Frequently asked questions

Does a registry mean I will receive a new medicine?

Not necessarily. The current ANR listing describes Enable as an observational registry for adults already prescribed BRIUMVI. Ask the research team how the protocol relates to your usual care.

Will I definitely be eligible if I have relapsing MS?

No. Eligibility is determined through the current study criteria and screening process. A diagnosis alone does not guarantee enrollment.

Can I leave the registry after I join?

Research participation is voluntary. The consent discussion should explain withdrawal and how previously collected information may be handled under the protocol.

Where can I verify the study details?

Start with ANR’s Current Studies page, the public registry record, and ANR staff. Study status and criteria can change.

What if I am not interested in Enable?

You can still review ANR’s current opportunities through Volunteer Today. Choosing not to participate does not change the value of ongoing MS care.

Practical scheduling and follow-up tips

Before you agree to a screening visit, ask about the expected time commitment in a way that matches your routine. Find out how often visits occur, whether questionnaires can be completed at home, what happens if you are ill or traveling, and whether a caregiver may join a discussion. Bring a calendar so you can consider work, transportation, family obligations, and other appointments. A registry should be workable enough that you can take part without hiding problems or skipping important clinical care.

Keep a single list of study contacts, routine-care contacts, and pharmacy contacts. If you have a new concern, use the instructions from your treating clinician and the consent materials to decide whom to call. Research staff may need to record information related to the protocol, while your clinical team may need to evaluate symptoms or make treatment decisions. Clear communication helps each team do its role.

Why the public study record is helpful

Public registries such as ClinicalTrials.gov provide a plain starting point for learning about a study’s official title, identifier, sponsor, design, and status. They are useful alongside—not instead of—the conversation with local staff. A registry record cannot account for a person’s whole medical history or confirm local availability on a particular day. ANR’s current listing and the research team should be your source for site-specific status, screening details, and next steps.

A final note about study status

Availability can change as sites open, screening goals are met, or a protocol is updated. Confirm the current status directly with ANR before making plans.

Take the next informed step

For Arizona adults with RMS who have been prescribed BRIUMVI, the Enable registry may be worth a factual conversation with ANR. Review the Current Studies page, make a short question list, and ask the research team about local availability, screening, privacy, and the current protocol. The team can provide study-specific answers without promising enrollment, safety, or personal benefit.

Educational disclaimer: This article is for general education only. It is not medical advice, a diagnosis, treatment recommendation, or a guarantee of study eligibility, enrollment, safety, or benefit. Speak with your own clinician about medical decisions. For emergency symptoms, call 911 or seek emergency care.